Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced the pricing of an upsized public offering of 6.5 million shares of common stock at $10.00 per share. The offering is expected to generate gross proceeds of $65.0 million before deducting expenses.
The company has granted underwriters a 30-day option to purchase up to an additional 975,000 shares at the public offering price. J.P. Morgan, Jefferies, and Evercore ISI are serving as joint book-running managers. The offering, made under a shelf registration statement, is expected to close on October 2, 2025.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced a proposed public offering of common stock worth $50.0 million. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million of shares at the public offering price, less underwriting discounts and commissions.
The offering will be managed jointly by J.P. Morgan, Jefferies, and Evercore ISI as book-running managers. The offering is being made through a shelf registration statement on Form S-3 that became effective on February 8, 2024. The completion of the offering is subject to market and other conditions.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced positive topline results from its Phase 2b RSVHR study of zelicapavir, a novel N-protein inhibitor for treating Respiratory Syncytial Virus (RSV) in high-risk adults. The study demonstrated a 6.7-day improvement in symptom resolution for patients with COPD, CHF, or age ≥75 (HR3 population).
Key findings include a lower hospitalization rate in the zelicapavir group (1.7%) versus placebo (5.0%), and a 4-5 day faster median time to undetectable viral load. The drug showed statistically significant improvement in Patient Global Impression of Severity scores and demonstrated a favorable safety profile. The study enrolled 186 subjects, with 121 receiving zelicapavir and 65 receiving placebo.
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, September 29 at 8:30 a.m. ET. The biotechnology company will present topline results from its Phase 2b RSVHR study evaluating zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults.
The live webcast will be accessible through the investors section of Enanta's website under "Events & Presentations". Participants joining by phone are encouraged to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on the company's website for approximately 30 days after the event.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the passing of its long-serving Chief Financial and Administrative Officer, Paul J. Mellett Jr., who had been with the company since 2003. During his tenure, Mellett played a pivotal role in establishing the company's finance department and led Enanta's IPO in 2013.
Mellett was instrumental in forging strategic partnerships, notably the 2006 collaboration with Abbott (now AbbVie) that led to the development of VIEKIRA PAK® and MAVYRET®/MAVIRET® for hepatitis C treatment, which have cured over one million patients globally. The company has appointed Harry R. Trout, III as interim principal financial officer and Kathleen S. Capps, CPA, as interim principal accounting officer.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases, has announced its participation in three major investor conferences in September 2025.
Management will present at the Cantor Global Healthcare Conference (September 3), H.C. Wainwright Global Investment Conference (September 9), and Baird Global Healthcare Conference (September 10). All presentations will be available via live webcast on the company's website, with replays archived for at least 30 days.
[]Enanta Pharmaceuticals (NASDAQ: ENTA) has filed a patent infringement lawsuit against Pfizer in the Unified Patent Court (UPC) of the European Union. The lawsuit concerns European Patent No. EP 4 051 265, which relates to coronavirus protease inhibitors used in Pfizer's COVID-19 antiviral medication, Paxlovid™.
The legal action targets Pfizer's activities across 18 EU countries participating in the UPC. The patent in question is based on Enanta's July 2020 application and is the European counterpart to U.S. Patent No. 11,358,953, which is already involved in ongoing U.S. litigation between the companies. Under UPC procedures, a hearing is expected within a 12-month timeframe, with a decision following weeks after.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q3 2025 financial results, with total revenue of $18.3 million from royalties on AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company posted a net loss of $18.3 million ($0.85 per share), improving from a $22.7 million loss in Q3 2024.
Key pipeline developments include: completion of enrollment in the RSVHR Phase 2 trial of zelicapavir for RSV treatment with topline data expected in September, ongoing IND-enabling studies for EPS-1421 (KIT inhibitor) for urticaria treatment, and progress toward selecting a STAT6 development candidate in 2H 2025. The company maintains a strong financial position with $204.1 million in cash and marketable securities, projected to fund operations into fiscal 2028.
XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.
Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.
DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, will participate in a virtual fireside chat at the H.C. Wainwright & Co. "HCW@Home" series. The event is scheduled for Tuesday, August 12, 2025 at 1:00 p.m. ET.
Investors can access the live webcast through Enanta's website in the "Events and Presentations" section or via direct registration. A replay will be available after the presentation and archived for at least 30 days.